Department of Ophthalmology, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Israel.
Department of Ophthalmology, Meir Medical Center, Kfar Saba, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Israel; and.
Retina. 2022 Aug 1;42(8):1529-1535. doi: 10.1097/IAE.0000000000003497.
Evaluating the impact of delayed care, secondary to coronavirus disease 2019 (COVID-19) pandemic lockdowns, on visual acuity in previously treated neovascular age-related macular degeneration (nAMD) patients.
This was a multicenter, retrospective, study of patients with nAMD previously treated with anti-VEGF injections who were followed up during 2019 (pre-COVID-19) and compared with patients with nAMD during 2020 (COVID-19).
A total of 1,192 patients with nAMD with a mean age of 81.5 years met the inclusion criteria. Of these, 850 patients were assessed in 2019 (pre-COVID-19) and 630 patients were assessed in 2020 (COVID-19). Three hundred eight patients were assessed through both 2019 and 2020 and thus were included in both cohorts. There was no significant difference between 2020 and 2019 in baseline and change in best-corrected visual acuity (BCVA; P = 0.342 and P = 0.911, respectively). The mean number of anti-VEGF injections was significantly lower (5.55 vs. 6.13, P < 0.01), with constant lower ratio of injections per patient in the COVID-19 period. Baseline BCVA (0.859, P < 0.01), number of injections (-0.006, P = 0.01), and age (0.003, P < 0.01) were predictors of final BCVA.
In patients with nAMD, delayed care secondary to COVID-19 pandemic lockdowns has no statistically significant impact on BCVA. Best-corrected visual acuity, older age, and lower number of yearly anti-VEGF injections are predictors for decrease BCVA.
评估因 2019 年冠状病毒病（COVID-19）大流行封锁而导致的延迟治疗对既往接受抗血管内皮生长因子（VEGF）注射治疗的新生血管性年龄相关性黄斑变性（nAMD）患者视力的影响。
这是一项多中心、回顾性研究，纳入了 nAMD 患者，这些患者既往接受过抗 VEGF 注射治疗，并在 2019 年（COVID-19 之前）和 2020 年（COVID-19 期间）进行了随访。
共有 1192 名 nAMD 患者符合纳入标准，平均年龄为 81.5 岁。其中，850 名患者在 2019 年（COVID-19 之前）进行了评估，630 名患者在 2020 年（COVID-19 期间）进行了评估。有 308 名患者在 2019 年和 2020 年均进行了评估，因此被纳入了两个队列。2020 年和 2019 年的基线和最佳矫正视力（BCVA）变化之间没有显著差异（P = 0.342 和 P = 0.911）。抗 VEGF 注射的平均次数明显较低（5.55 次比 6.13 次，P < 0.01），COVID-19 期间每位患者的注射比例也较低。基线 BCVA（0.859，P < 0.01）、注射次数（-0.006，P = 0.01）和年龄（0.003，P < 0.01）是最终 BCVA 的预测因素。
在 nAMD 患者中，COVID-19 大流行封锁导致的延迟治疗对 BCVA 无统计学显著影响。BCVA 下降的预测因素包括最佳矫正视力、年龄较大和每年接受的抗 VEGF 注射次数较少。
